HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and safety of warfarin vs. antiplatelet therapy in patients with systolic heart failure and sinus rhythm: a systematic review and meta-analysis of randomized controlled trials.

AbstractBACKGROUND AND PURPOSE:
Heart failure is an independent risk factor for stroke. Anticoagulation is effective for prevention of cardio-embolic stroke secondary to atrial fibrillation or mechanical heart valves but is of uncertain benefit in heart failure patients. We performed this meta-analysis to obtain the best estimates of the efficacy and safety of warfarin as compared with antiplatelet therapy in patients with systolic heart failure who are in sinus rhythm.
METHODS AND RESULTS:
A systematic search was performed using PubMed and Central Register of Controlled Trials databases for all randomized controlled trials, which compare warfarin with antiplatelet therapy given for at least one-month in heart failure patients with sinus rhythm and report at least one of the following outcomes: ischemic stroke, death, myocardial infarction, hospitalization due to worsening heart failure, intracranial hemorrhage, and major hemorrhage. Four randomized controlled trials involving adjusted-dose warfarin (4187 subjects) were included. When compared with antiplatelet therapy, warfarin reduced ischemic stroke by 0·74% per year (RR 0·49; 95% CI: 0·32-0·73: P = 0·0006; Number needed to treat = 135) but increased major hemorrhage by 0·99% per year (RR 2·15; 95% CI: 1·55-2·99: P < 0·00001; Number needed to harm = 101). Warfarin did not significantly affect the risk of death, myocardial infarction, hospitalization due to heart failure or intracranial hemorrhage as compared with antiplatelet therapy.
CONCLUSIONS:
Warfarin as compared with antiplatelet therapy reduces risk of ischemic stroke, does not significantly affect death, myocardial infarction, hospitalization due to heart failure or intracranial hemorrhage and increases major hemorrhage in heart failure patients who are in sinus rhythm.
AuthorsAaron Yl Liew, John W Eikelboom, Stuart J Connolly, Martin O' Donnell, Robert G Hart
JournalInternational journal of stroke : official journal of the International Stroke Society (Int J Stroke) Vol. 9 Issue 2 Pg. 199-206 (Feb 2014) ISSN: 1747-4949 [Electronic] United States
PMID23506160 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
Copyright© 2013 The Authors. International Journal of Stroke © 2013 World Stroke Organization.
Chemical References
  • Anticoagulants
  • Platelet Aggregation Inhibitors
  • Warfarin
Topics
  • Anticoagulants (pharmacology, therapeutic use)
  • Heart Failure, Systolic (drug therapy)
  • Heart Rate (drug effects)
  • Humans
  • Platelet Aggregation Inhibitors (pharmacology, therapeutic use)
  • Randomized Controlled Trials as Topic
  • Warfarin (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: